// App-Quantinova.ai

1609 : Comprehensive multi-omic analysis of circulating tumor cells isolated from a metastatic triple-negative breast cancer patient to identify pathogenic genomic aberrations

Researchers

Presenter

  • Kellie Howard

Principal Investigators

  • Sharon Austin

  • Arturo Ramirez

  • Heather Collins

  • Amanda Leonti

  • Lindsey Maassel

  • Jackie Stilwell

  • Eric Kaldjian

  • Leila Ritter

  • Debbie Boles

  • James Cox

  • Fang Yin Lo

  • Kerry Deutsch

  • Christopher Subia

  • Tuuli Saloranta

  • Nicole Heying

Medical Centers

  • Laboratory Corporation of Amcerica, Research Triangle Park, NC

  • University of Washington, Seattle, WA

  • Rarecyte, Seattle, WA

  • LaCorp Clinical Trials, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Solid malignancies

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Anaplastic lymphoma Kinase

  • Ataxia Telangiectasia And Rad3-Related Protein

  • Neurogenic locus notch homolog protein 1

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphatase and tensin homolog

  • Circulating tumor cells

  • Collagen alpha-1(I) chain

  • erb-b2 receptor tyrosine kinase 2

  • HRas Proto-Oncogene, GTPase

  • Janus kinase 3

  • Liver kinase B1

  • Major Histocompatibility Complex, Class I, A

  • Tumor protein p53

  • White Blood Cell

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • TP53

  • Tamsulosin Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved